EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Friday, March 29th 2019 at 6:03pm UTC CAMBRIDGE, Massachusetts–(BUSINESS WIRE)– Ultivue, un développeur de tests d’identification et de quantification des biomarqueurs tissulaires destinés aux laboratoires de recherche translationnelle et en pathologie, et Definiens, une société pionnière de l’analyse des images basée sur l’intelligence artificielle, ont annoncé aujourd’hui une collaboration visant …
Plus »Definiens and Ultivue Announce a Collaboration to Co-Develop Joint Offerings in Multiplexed Immunofluorescence (IF) and AI Enabled Digital Image Analysis
Friday, March 29th 2019 at 3:11pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, and Definiens, a pioneer in artificial intelligence (AI) based image analysis, today announced a collaboration to expand Definiens standardized IO-Panel capabilities to IF. The …
Plus »Bicycle Therapeutics to Present Preclinical Data on EphA2 and Nectin-4 Bicycle Toxin Conjugate Programs, as well as a CD137 Immune Oncology Program, at the American Association for Cancer Research Annual Meeting
Friday, March 29th 2019 at 12:00pm UTC CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)– Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle™) product platform, announced today that Bicycle scientists have been selected to present two oral presentations at the American Association for …
Plus »bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding ?A-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia (TDT) Who Do Not Have ?0/?0 Genotype
Friday, March 29th 2019 at 11:44am UTC First gene therapy recommended for approval in the EU for TDT Treatment with ZYNTEGLO has been shown to help eliminate the need for chronic blood transfusions in patients with TDT ZYNTEGLO is bluebird bio’s first gene therapy submitted for regulatory approval CAMBRIDGE, Mass.–(BUSINESS …
Plus »Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
Friday, March 29th 2019 at 10:30am UTC —PHYOX™1 Investigators Reported Potent, Durable Response in Phase 1 Study in Patients with PH1 and PH2 at German Society of Pediatric Nephrology 50th Annual Meeting— —Company Announces Initiation of Participant Screening for PHYOX2 Pivotal Trial in PH1 and PH2— CAMBRIDGE, Mass.–(BUSINESS WIRE)– Dicerna™ …
Plus »Quanterix Appoints Amol Chaubal as Chief Financial Officer
Thursday, March 28th 2019 at 8:00pm UTC Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth LEXINGTON, Mass.–(BUSINESS WIRE)– Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has …
Plus »Ultivue releases breakthrough innovations for multiplex IHC: 16-marker whole-slide visualization and high marker co-localization in FFPE tissue
Thursday, March 28th 2019 at 1:35pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue today unveiled the expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology through comprehensive visualization of a whole slide 16-marker multiplex assay in tissue. Until now, this level of multiplexing relied on complex instrumentation to map marker location …
Plus »American Renal Associates Holdings, Inc. Provides Update on Audit Committee Review and Announces Organizational Changes
Wednesday, March 27th 2019 at 8:15pm UTC Company to Restate Certain Financial Results Company Announces Resignation of Jason Boucher as Chief Financial Officer and Appointment of Mark Herbers as Interim Chief Financial Officer Company Remains Committed to Providing High Quality Care to Patients, Together with its Physician Partners BEVERLY, Mass.–(BUSINESS …
Plus »Immuno-Oncology Company Elicio Therapeutics Launches with Novel Vaccine & Immunotherapy Platform to Treat an Array of Cancers
Wednesday, March 27th 2019 at 1:30pm UTC $30 Million Financing Backing MIT-Developed Amphiphile Platform to Target a Wide-Range of Immunogens to the Lymph Nodes, the “Brain Center” of the Immune Response CAMBRIDGE, Mass.–(BUSINESS WIRE)– Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, launched today …
Plus »Imara Appoints Chief Medical Officer
Wednesday, March 27th 2019 at 12:00pm UTC 25+-Year Veteran of Large Pharma, Willem H. Scheele, M.D., to Progress Company’s Clinical Development Program for Sickle Cell Disease, Thalassemia, and Pipeline CAMBRIDGE, Mass.–(BUSINESS WIRE)– Imara Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, today announced it has …
Plus »
